Long-term hemodynamic response to captopril (SQ 14,225) in hypertensive hemodialysis patients. 1983

H Hirakata, and K Iseki, and K Onoyama, and H Kumagai, and S Fujimi, and T Omae

The long-term effect of treatment with captopril was observed in 7 hypertensive patients on maintenance hemodialysis who had been refractory to combined antihypertensive therapy with propranolol and hydralazine. Captopril showed a potent hypotensive effect in all the subjects throughout the study period of 6 months. The blood-pressure reduction during treatment with captopril was associated with a decrease in total peripheral resistance. Cardiac index increased significantly due to a significant increment in heart rate at the 6th month. Plasma renin activity increased significantly at the 3rd month, whereas it decreased at the 6th month. No significant correlation was observed between the blood-pressure response and the pre-treatment level of plasma renin activity.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D009400 Nephrosclerosis Hardening of the KIDNEY due to infiltration by fibrous connective tissue (FIBROSIS), usually caused by renovascular diseases or chronic HYPERTENSION. Nephrosclerosis leads to renal ISCHEMIA. Nephroscleroses
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H Hirakata, and K Iseki, and K Onoyama, and H Kumagai, and S Fujimi, and T Omae
September 1981, Clinical nephrology,
H Hirakata, and K Iseki, and K Onoyama, and H Kumagai, and S Fujimi, and T Omae
January 1985, Indian journal of dermatology, venereology and leprology,
H Hirakata, and K Iseki, and K Onoyama, and H Kumagai, and S Fujimi, and T Omae
January 1988, Archives internationales de pharmacodynamie et de therapie,
H Hirakata, and K Iseki, and K Onoyama, and H Kumagai, and S Fujimi, and T Omae
March 1982, Experientia,
H Hirakata, and K Iseki, and K Onoyama, and H Kumagai, and S Fujimi, and T Omae
February 1981, Postgraduate medical journal,
H Hirakata, and K Iseki, and K Onoyama, and H Kumagai, and S Fujimi, and T Omae
December 1979, European journal of pharmacology,
H Hirakata, and K Iseki, and K Onoyama, and H Kumagai, and S Fujimi, and T Omae
January 1978, Progress in cardiovascular diseases,
H Hirakata, and K Iseki, and K Onoyama, and H Kumagai, and S Fujimi, and T Omae
April 1982, The American journal of cardiology,
H Hirakata, and K Iseki, and K Onoyama, and H Kumagai, and S Fujimi, and T Omae
June 1982, Archives des maladies du coeur et des vaisseaux,
H Hirakata, and K Iseki, and K Onoyama, and H Kumagai, and S Fujimi, and T Omae
February 1981, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!